Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Annals of the Rheumatic Diseases

• Publication date

  2018-01-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/annrheumdis-2017-212224PMID 29371202PMCID PMC6037302
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Relationship of Longitudinal Levels of Complement Bb During Pregnancy with Preeclampsia

  2016cited by this paper
• Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study.

  2016cited by this paper
• Prevention of Defective Placentation and Pregnancy Loss by Blocking Innate Immune Pathways in a Syngeneic Model of Placental Insufficiency

  2015cited by this paper
• Histopathology in the placentae of women with antiphospholipid antibodies: A systematic review of the literature.

  2015cited by this paper
• Complement Split Products in Amniotic Fluid in Pregnancies Subsequently Developing Early-Onset Preeclampsia

  2015cited by this paper
• Classical Complement Pathway Activation in the Kidneys of Women With Preeclampsia

  2015cited by this paper
• Predictors of Pregnancy Outcomes in Patients With Lupus

  2015cited by this paper
• Urinary Excretion of C5b‐9 is Associated With the Anti‐Angiogenic State in Severe Preeclampsia

  2015cited by this paper
• Assessment of Cell-Cycle Arrest Biomarkers to Predict Early and Delayed Acute Kidney Injury

  2015cited by this paper
• Complement — tapping into new sites and effector systems

  2014cited by this paper
• Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements

  2014cited by this paper
• Maternal and Fetal Alternative Complement Pathway Activation in Early Severe Preeclampsia

  2014cited by this paper
• Urinary Excretion of C5b-9 in Severe Preeclampsia: Tipping the Balance of Complement Activation in Pregnancy

  2013cited by this paper
• Primary anti-phospholipid syndrome: any role for serum complement levels in predicting pregnancy complications?

  2012cited by this paper
• Complementemia and obstetric outcome in pregnancy with antiphospholipid syndrome

  2012cited by this paper
• Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies.

  2012cited by this paper
• Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome

  2012cited by this paper
• Autoantibody-Mediated Complement C3a Receptor Activation Contributes to the Pathogenesis of Preeclampsia

  2012cited by this paper
• Preeclampsia Is Characterized by Placental Complement Dysregulation

  2012cited by this paper
• Mutations in Complement Regulatory Proteins Predispose to Preeclampsia: A Genetic Analysis of the PROMISSE Cohort

  2011cited by this paper
• Classical complement activation as a footprint for murine and human antiphospholipid antibody‐induced fetal loss

  2011cited by this paper
• Targeted inhibition of complement activation prevents features of preeclampsia in mice.

  2011cited by this paper
• Dysregulated complement activation as a common pathway of injury in preeclampsia and other pregnancy complications.

  2010cited by this paper
• The interrelationship of complement‐activation fragments and angiogenesis‐related factors in early pregnancy and their association with pre‐eclampsia

  2010cited by this paper
• Complement activation in patients with primary antiphospholipid syndrome

  2008cited by this paper
• Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies.

  2007cited by this paper
• Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction

  2006cited by this paper
• A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice.

  2005cited by this paper
• TNF-α Is a Critical Effector and a Target for Therapy in Antiphospholipid Antibody-Induced Pregnancy Loss1

  2005cited by this paper
• Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome.

  2003cited by this paper
• Complement C3 Activation Is Required for Antiphospholipid Antibody-induced Fetal Loss

  2002cited by this paper
• Immunology of reproduction: protecting the placenta.

  2000cited by this paper
• Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

  1997cited by this paper
• Anticardiolipin IgG subclasses: association of IgG2 with arterial and/or venous thrombosis.

  1997cited by this paper
• Decay-accelerating factor protects human trophoblast from complement-mediated attack.

  1995cited by this paper
• Susceptibility of human trophoblast to killing by human complement and the role of the complement regulatory proteins.

  1993cited by this paper
• Activation of the Complement Pathway: Comparison of Normal Pregnancy, Preeclampsia, and Systemic Lupus Erythematosus During Pregnancy

  1992cited by this paper
• Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy.

  1992cited by this paper
• Preferential expression of the complement regulatory protein decay accelerating factor at the fetomaternal interface during human pregnancy.

  1990cited by this paper
• Complement component deposition in uteroplacental (spiral) arteries in normal human pregnancy.

  1987cited by this paper

• C3a and TNF-α as potential biomarkers in recurrent spontaneous abortion: insights from integrated protein and gene expression analysis

  2026cites this paper
• Pregnancy management in women with rheumatic diseases: modern treatment methods

  2026cites this paper
• Obstetric antiphospholipid syndrome: Advances in pathogenesis.

  2026cites this paper
• Coagulation parameter-based nomogram for the diagnosis of obstetric antiphospholipid syndrome and its subtypes

  2026cites this paper
• Endothelial Glycocalyx: The Missing Link Between Angiogenic Imbalance in Preeclampsia and Systemic Inflammation in HELLP Syndrome

  2025cites this paper
• Risk factors for adverse pregnancy outcomes in systemic lupus erythematosus: a meta-analysis and systemic review

  2025cites this paper
• Complement System Inhibitors in Nephrology: An Update—Narrative Review

  2025cites this paper
• Systemic Lupus Erythematosus in Pregnancy

  2025cites this paper
• Uteroplacental microvascular remodeling in health and disease

  2025cites this paper
• Adverse Pregnancy Outcomes in Sjogren's Disease Compared to Controls: An Interdisciplinary Approach with Maternal–Fetal Medicine

  2025cites this paper
• Mechanism of antiphospholipid antibody-mediated thrombosis in antiphospholipid syndrome

  2025cites this paper
• Plasmapheresis for lowering the risks of placenta-associated complications in antiphospholipid syndrome

  2025cites this paper
• The conditions that patients with systemic lupus erythematosus should fulfill before pregnancy to optimize outcomes: a large-scale multicenter cohort study from China

  2025cites this paper
• Inhibiting the alternative pathway of complement by reducing systemic complement factor B: Randomized, double-blind, placebo-controlled phase 1 studies with Sefaxersen.

  2025cites this paper
• Methodology of the development of the EULAR Antiphosholipid Syndrome Disease Activity Score (EAPSDAS)

  2025cites this paper
• Risk stratification and subgroup analysis of systemic lupus erythematosus patients with pregnancy: based on a 13-year multicenter cohort study

  2025cites this paper
• Complement proteins, annexin V, and angiogenic markers in placental tissue of autoimmune disease patients.

  2025cites this paper
• Construction and application of fetal loss risk model in systemic lupus erythematosus patients with mild disease severity

  2024cites this paper
• Case report: Additional use of hydroxychloroquine in treatment‐resistant recurrent cerebral infarctions with antiphospholipid antibody syndrome

  2024cites this paper
• Antiphospholipid syndrome pathogenesis in 2023: an update of new mechanisms or just a reconsideration of the old ones?

  2024cites this paper
• Pregnancy in antiphospholipid syndrome: what should a rheumatologist know?

  2024cites this paper
• Vascular damage in systemic lupus erythematosus

  2024cites this paper
• The Role of Complement in Kidney Disease: Conclusions From a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

  2024cites this paper
• Risk Factors for Adverse Pregnancy Outcomes in Patients with Antiphospholipid Syndrome

  2024cites this paper
• Preterm birth, a consequence of immune deviation mediated hyperinflammation.

  2024cites this paper
• Can complement activation be the missing link in antiphospholipid syndrome?

  2024cites this paper
• Antiphospholipid antibodies and the risk of adverse pregnancy outcomes in patients with systemic lupus erythematosus: a systematic review and meta-analysis

  2024cites this paper
• Pregnancy as a susceptible state for thrombotic microangiopathies

  2024cites this paper
• Association Between 25‐hydroxyvitamin D Levels and Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus

  2024cites this paper
• B Cell Responses to the Placenta and Fetus

  2024cites this paper
• Correlation of placental lesions in patients with systemic lupus erythematosus, antiphospholipid syndrome and non-criteria obstetric antiphospholipid syndrome and adverse perinatal outcomes.

  2023cites this paper
• Machine Learning Models for Predicting Adverse Pregnancy Outcomes in Pregnant Women with Systemic Lupus Erythematosus

  2023cites this paper
• Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management

  2023cites this paper
• Control of lupus activity during pregnancy via the engagement of IgG sialylation: novel crosstalk between IgG sialylation and pDC functions

  2023cites this paper
• Low complement levels are related to poor obstetric outcomes in women with obstetric antiphospholipid syndrome. The EUROAPS Registry Study Group.

  2023cites this paper
• Variations of C3 and C4 Before and During Pregnancy in Systemic Lupus Erythematosus: Association With Disease Flares and Obstetric Outcomes

  2023cites this paper
• Antiphospholipid antibodies induce proinflammatory and procoagulant pathways in endothelial cells

  2023cites this paper
• High-throughput sequencing technology facilitates the discovery of novel biomarkers for antiphospholipid syndrome

  2023cites this paper
• Role of β2‐glycoprotein I in the pathogenesis of the antiphospholipid syndrome

  2023cites this paper
• Immunobiology of pregnancy: from basic science to translational medicine.

  2023cites this paper
• Complement therapeutics are coming of age in rheumatology

  2023cites this paper
• Differentiating Between Activation via the Lectin or the Classical Complement Pathway in Patients with Systemic Lupus Erythematosus.

  2023cites this paper
• Assessing disease activity and damage in antiphospholipid syndrome.

  2023cites this paper
• The pathogenesis of obstetric APS: a 2023 update.

  2023cites this paper
• Preconception clinical factors related to adverse pregnancy outcomes in patients with systemic lupus erythematosus or primary Sjögren’s syndrome: a retrospective cohort study

  2023cites this paper
• Antiphospholipid antibody carriers and patients with quiescent antiphospholipid syndrome show persistent subclinical complement activation.

  2023cites this paper
• Complement levels during the first trimester predict disease flare and adverse pregnancy outcomes in systemic lupus erythematosus: A network meta-analysis on 532 pregnancies.

  2023cites this paper
• Complement biomarkers in the antiphospholipid syndrome - Approaches to quantification and implications for clinical management.

  2023cites this paper
• Mesenchymal stem cell secretome ameliorates over-expression of soluble fms-like tyrosine kinase-1 (sFlt-1) and fetal growth restriction (FGR) in animal SLE model

  2023cites this paper
• Immunology of pregnancy and reproductive health in autoimmune rheumatic diseases. Update from the 11th International Conference on Reproduction, Pregnancy and Rheumatic Diseases.

  2022cites this paper
• Pathogenesis, Diagnosis and Management of Obstetric Antiphospholipid Syndrome: A Comprehensive Review

  2022cites this paper
• Additional risk factors associated with thrombosis and pregnancy morbidity in a unique cohort of antiphospholipid antibody-positive patients

  2022cites this paper
• Beyond Systemic Lupus Erythematosus and Anti-Phospholipid Syndrome: The Relevance of Complement From Pathogenesis to Pregnancy Outcome in Other Systemic Rheumatologic Diseases

  2022cites this paper
• Intertwined pathways of complement activation command the pathogenesis of lupus nephritis.

  2022cites this paper
• Predictors Associated with Adverse Pregnancy Outcomes in a Cohort of Women with Systematic Lupus Erythematosus from Romania—An Observational Study (Stage 2)

  2022cites this paper
• Chronic Inflammatory Placental Disorders Associated With Recurrent Adverse Pregnancy Outcome

  2022cites this paper
• The Impact of Preeclampsia in Lupus Nephritis

  2022cites this paper
• Pregnancy-related complications in systemic lupus erythematosus.

  2022cites this paper
• Placental damage in pregnancies with systemic lupus erythematosus: A narrative review

  2022cites this paper
• Pathophysiology of Placenta in Antiphospholipid Syndrome

  2022cites this paper
• Erythrocyte complement receptor 1 (ECR1) and erythrocyte-bound C4d (EC4d) in the prediction of poor pregnancy outcomes in systemic lupus erythematosus (SLE)

  2022cites this paper
• Contributions of animal models to mechanistic understandings of antibody‐dependent disease and roles of the amplification loop

  2022cites this paper
• Serum beta-2 microglobulin as a predictor of nephritis, disease activity, and damage score in systemic lupus erythematosus: a cross-sectional study

  2022cites this paper
• Disease activity at conception predicts lupus flare up to two years after birth: A multicentre long term follow-up study.

  2022cites this paper
• Alternative pathway activation in pregnancy, a measured amount “complements” a successful pregnancy, too much results in adverse events

  2022cites this paper
• Early Prediction of Adverse Pregnancy Outcome in Women with Systemic Lupus Erythematosus, Antiphospholipid Syndrome, or Non-Criteria Obstetric Antiphospholipid Syndrome

  2022cites this paper
• Spatiotemporal Patterns of Adverse Pregnancy Outcomes in Rural Areas of Henan, China

  2022cites this paper
• Isolation of extracellular vesicles from bitch's amnion-derived cells culture and their CD59 expression: Preliminary results.

  2022cites this paper
• The complement system and human autoimmune diseases.

  2022cites this paper
• Review of the immune mechanisms of preeclampsia and the potential of immune modulating therapy.

  2021cites this paper
• The Complement System, T Cell Response, and Cytokine Shift in Normotensive versus Pre-Eclamptic and Lupus Pregnancy

  2021cites this paper
• An Update on Antiphospholipid Syndrome

  2021cites this paper
• Effects of anti‐beta 2‐glycoprotein 1 antibodies and its association with pregnancy‐related morbidity in antiphospholipid syndrome

  2021cites this paper
• A Review of Complement Activation in SLE

  2021cites this paper
• Correlations of serum beta 2-microglobulin level with disease activity and renal involvement in patients with systemic lupus erythematosus

  2021cites this paper
• Editorial: Innate Immunity in Normal and Adverse Pregnancy

  2021cites this paper
• Immunological and physiopathological approach of COVID-19 in pregnancy

  2021cites this paper
• 24 The role of complement and complement inhibition in APS pregnancy

  2021cites this paper
• Outcomes of planned pregnancy in patients with systemic lupus erythematosus and their neonates

  2021cites this paper
• Early ADAMTS13 testing associates with pre-eclampsia occurrence in antiphospholipid syndrome.

  2021cites this paper
• Membrane cofactor protein (MCP; CD46): deficiency states and pathogen connections

  2021cites this paper
• Low Preconception Complement Levels Are Associated with Adverse Pregnancy Outcomes in a Multicenter Study of 260 Pregnancies in 197 Women with Antiphospholipid Syndrome or Carriers of Antiphospholipid Antibodies

  2021cites this paper
• Management of Pregnancy in Lupus.

  2021cites this paper
• Biochemical and clinical predictors in pregnant women with antiphospholipid syndrome and systemic lupus erythematosus: comprehensive update

  2021cites this paper
• Complement and the prothrombotic state.

  2021cites this paper
• Antiphospholipid Antibody Assays in 2021: Looking for a Predictive Value in Addition to a Diagnostic One

  2021cites this paper
• Preconception, pregnancy, and lactation in systemic lupus erythematosus patients

  2021cites this paper
• Pregnancy Counseling in Rheumatic Diseases: Where Science Meets the Steps

  2021cites this paper
• Quantitative Alterations in Complement Alternative Pathway and Related Genetic Analysis in Severe Phenotype Preeclampsia

  2021cites this paper
• Advancing research on recurrent pregnancy loss: Overcoming obstacles and opportunities for translation

  2021cites this paper
• Consultation préconceptionnelle dans les maladies auto-immunes systémiques

  2021cites this paper
• Antibodies and diagnostic tests in antiphosholipid syndrome

  2021cites this paper
• Clinical features associated with pregnancy outcomes in women with positive antiphospholipid antibodies and previous adverse pregnancy outcomes: a real-world prospective study

  2020cites this paper
• The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS

  2020cites this paper
• The antiphospholipid syndrome – often overlooked cause of vascular occlusions?

  2020cites this paper
• Targeted therapies in systemic sclerosis, myositis, antiphospholipid syndrome, and Sjögren's syndrome.

  2020cites this paper
• Maternal and perinatal outcomes of pregnancies in systemic lupus erythematosus: A nationwide population-based study.

  2020cites this paper
• Effect of hypocomplementemia on perinatal outcomes of pregnancies with autoimmune disorders

  2020cites this paper
• A review of fetal and neonatal consequences of maternal systemic lupus erythematosus

  2020cites this paper
• A review of the alternative pathway of complement and its relation to HELLP syndrome: is it time to consider HELLP syndrome a disease of the alternative pathway

  2020cites this paper